SAN JOSE, Calif., Feb. 23, 2026 — Anixa Biosciences announced that immunology leader Jose Conejo-Garcia, M.D., Ph.D., will keynote the South Carolina Clinical & Translational Research Institute (SCTR) 2026 Retreat, where he will highlight advances in the company’s FSHR-mediated CAR-T cell therapy platform. The keynote will feature insights from Anixa’s ongoing Phase 1 clinical trial of liraltagene autoleucel (lira-cel) targeting recurrent ovarian cancer, underscoring the growing translational momentum behind engineered cell therapies in oncology.
Science Significance
The keynote centers on breakthrough progress in cell-based immunotherapy, particularly Anixa’s novel FSHR-targeted CAR-T technology, which represents a differentiated approach within the rapidly evolving cell therapy landscape. Unlike traditional CAR-T constructs, this platform leverages the follicle-stimulating hormone receptor (FSHR), selectively expressed on ovarian tissue and tumor vasculature but largely absent from healthy organs. This specificity enhances tumor targeting while reducing off-tumor toxicity risks. The investigational therapy, liraltagene autoleucel, is currently being evaluated in women with recurrent ovarian cancer who have failed multiple prior therapies. By focusing on receptor-mediated tumor recognition, the platform advances precision immuno-oncology and expands the scientific frontier of solid tumor CAR-T applications, historically more challenging than hematologic indications.
Regulatory Significance
From a regulatory standpoint, the advancement of FSHR-mediated CAR-T therapy reinforces the growing complexity of Advanced Therapy Medicinal Products (ATMPs) and the stringent frameworks governing their development. Ongoing Phase 1 evaluation requires rigorous adherence to Good Clinical Practice (GCP), patient safety monitoring, and cellular manufacturing controls. Regulatory agencies are increasingly focused on vector safety, persistence monitoring, cytokine release risk management, and long-term follow-up protocols for gene-modified therapies. Showcasing early clinical findings in translational forums such as SCTR strengthens regulatory transparency, scientific peer validation, and future submission readiness for expanded trials.
Business Significance
Advertisement
The keynote platform provides strategic visibility for Anixa’s oncology pipeline and reinforces its positioning within the competitive cell therapy sector. By presenting at a translational research forum that convenes industry, academia, and clinical stakeholders, the company enhances partnership opportunities and investor confidence. Anixa’s broader portfolio includes cancer vaccines and collaborative programs with leading institutions, reflecting a diversified immuno-oncology strategy. Visibility of its CAR-T innovation and clinical progress supports long-term commercialization planning and strengthens its competitive differentiation in next-generation cell therapy development.
Patients’ Significance
For patients with recurrent ovarian cancer, the scientific progress highlighted in the keynote carries profound therapeutic implications. This patient population often faces limited treatment options and poor long-term prognosis after standard therapies fail. Targeted cellular immunotherapies such as liraltagene autoleucel offer the potential for durable tumor control, immune-mediated remission, and personalized therapeutic intervention. Continued clinical advancement ensures patient access to innovative investigational therapies while expanding hope for improved survival outcomes in difficult-to-treat gynecologic malignancies.
Policy Significance
The prominence of cell therapy innovation at translational research forums reflects broader healthcare policy priorities supporting regenerative medicine, immuno-oncology funding, and advanced manufacturing infrastructure. Governments and research ecosystems are increasingly investing in cell therapy acceleration programs, regulatory harmonization, and clinical trial network expansion. Showcasing translational progress reinforces the importance of sustained policy backing for high-complexity biologics that require specialized manufacturing, workforce expertise, and long-term reimbursement planning.
The upcoming keynote by Dr. Conejo-Garcia positions Anixa Biosciences at the forefront of translational immuno-oncology dialogue, spotlighting its differentiated CAR-T platform and early clinical momentum. As solid tumor cell therapies advance from experimental science toward regulatory and commercial reality, collaborative research forums such as SCTR play a pivotal role in shaping scientific validation, investment confidence, and patient access pathways. Continued progress in receptor-targeted cellular immunotherapy signals a transformative era for ovarian cancer treatment and the broader oncology innovation landscape.
Source: Anixa Biosciences press release
